BCG

Global Vaccine Technologies Market Report 2024, Featuring Abbott, Astrazeneca, Bavarian Nordic, Emergent Biosolutions, GSK, Merck, Mitsubishi Tanabe Pharma, Panacea Biotec, Pfizer & Sanofi - ResearchAndMarkets.com

Retrieved on: 
Monday, February 12, 2024
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Acquisition, Attenuated vaccine, Immunization, BCG, Physician, Cancer, Influenza, ESG, Government, Allergy, Vaccine, Rotavirus, MMR, Disease, HPV, Infection, Diphtheria, Hepatitis, Research, Human, Pharmaceutical industry

Continuous improvements in vaccine design, delivery technologies and manufacturing will also boost market growth.

Key Points: 
  • Continuous improvements in vaccine design, delivery technologies and manufacturing will also boost market growth.
  • The global vaccine technologies market is segmented in this report by technology, disease, age, and region.
  • It discusses the market determinants, which act as motivating or restraining factors and provides insights to stakeholders and potential entrants.
  • This study looks at research and development (R&D) spending, increasing competition and new technologies, which are giving direction to the market.

Thailand BOI Says 2023 Investment Applications up 43% to USD 24 Billion as Large FDI Projects Soar

Retrieved on: 
Friday, February 9, 2024
Policy, Republic, EEC, BCG, Government House, Investment, FDI, Growth, EV, Electronics, Steel, Innovation, Steam, LTD, BOI, RDF, USD, Renewable energy

Moreover, the fact that the Prime Minister Srettha Thavisin, himself, led several investment promotion roadshows, has significantly raised investors' confidence and put Thailand on the radars of key investment communities."

Key Points: 
  • Moreover, the fact that the Prime Minister Srettha Thavisin, himself, led several investment promotion roadshows, has significantly raised investors' confidence and put Thailand on the radars of key investment communities."
  • We also believe investments are likely to grow due to the continued flow of FDI, especially in our priority sectors."
  • The total number of applications for investment promotion filed last year by investors, both local and foreign, increased 16% to 2,307 projects, worth a combined 24 billion dollars investment, up 43% from a revised 16.9 billion dollars in 2022.
  • Singapore came in second with 194 projects worth a combined 3.5 billion dollars of investment, boosted by large projects applications from Singapore-based affiliates of international companies in sectors including solar cells and electronics.

ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG

Retrieved on: 
Monday, February 5, 2024
Oncology, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Gemcitabine, Quality of life, Rated R, Docetaxel, NAI, NMIBC, Patient, Safety, CIS, UCLA, DSS, Pros, PRO, Incidence, Progression-free survival, Cancer, Diagnosis, FDA, SOC, Medicine, Cystectomy, Global health, Experiment (probability theory), DFS, Pembrolizumab, Carcinoma in situ, PDUFA, Associate, Bladder cancer, BCG, BLA, Bacillus

Overall, participants who achieved a complete response with the novel combination therapy reported better physical function by month six of the study than those who did not achieve a complete response.

Key Points: 
  • Overall, participants who achieved a complete response with the novel combination therapy reported better physical function by month six of the study than those who did not achieve a complete response.
  • “Many current therapies for bladder cancer slow disease progression but can cause debilitating side effects,” said Principal Investigator Karim Chamie, M.D., Associate Professor of Urology at UCLA.
  • Bladder cancer is the 10th most-commonly diagnosed cancer, with approximately 80% of newly diagnosed cases being NMIBC.
  • Safety and efficacy have not been established by any Health Authority or Agency, including the FDA.

EmTech Invest: FD CAPITAL x GW Capital Hosts Global Economic Symposium in Davos in Collaboration with Stukkert&Co

Retrieved on: 
Thursday, February 1, 2024
Growth, Diplomacy, AI, Emtech, Government, Social media, VIP, AML, Agathis, UN, FD, Republic, BCG, Face, Typesetting

Davos, Switzerland--(Newsfile Corp. - February 1, 2024) - EmTech, a prominent technology and business solutions company, hosted a groundbreaking global economic symposium in Davos, Switzerland on January 16 2024.

Key Points: 
  • Davos, Switzerland--(Newsfile Corp. - February 1, 2024) - EmTech, a prominent technology and business solutions company, hosted a groundbreaking global economic symposium in Davos, Switzerland on January 16 2024.
  • The symposium featured keynotes, panel discussions, and interactive sessions that delve into the pressing issues shaping the global economy.
  • (On the left) Mark Minevich - is a Global Visionary that translates vision and strategy into action.
  • This exclusive gathering in 2024 was backed by international investors convened by FD CAPITAL and Swiss digital compliance experts from Green Wealth Capital.

Turn ideas into videos in minutes with Pictory's New Custom GPT - Simplifying Video Creation For Marketers

Retrieved on: 
Thursday, February 1, 2024
Microsoft PowerPoint, Research, Walmart, B2B, Climate change, University, APU, Marketing, GPT, Getty Images, Learning, Archive, BCG, Small business, Video game

SEATTLE, Feb. 1, 2024 /PRNewswire/ -- Pictory launches custom Pictory GPT to simplify video creation for marketers.

Key Points: 
  • SEATTLE, Feb. 1, 2024 /PRNewswire/ -- Pictory launches custom Pictory GPT to simplify video creation for marketers.
  • Take a simple idea like, "Create a video about preventing climate change that is 1-2 minutes long" and transform it into a FULL video in minutes.
  • These include the availability of additional languages for video narration, and a feature that will turn PowerPoint presentations into professional-looking videos in minutes.
  • With Pictory, corporate teams can now produce and share professional videos in minutes without hiring costly video editors or learning how to use complex video editing software.

Beacon Biosignals welcomes David Matthews, PhD, as Chief Business Officer

Retrieved on: 
Thursday, February 1, 2024
Sleep, Intelligence, Molecular biology, Software, Growth, MD, Boston Consulting Group, NIH, Therapy, Neuroscience, Machine learning, Patient, Biological engineering, Biosignal, Disease, Brain, Partner, Medicine, NSF, Medical device, EEG, Doctor of Philosophy, Princeton University, BCG, University, Health

BOSTON, Feb. 1, 2024 /PRNewswire/ -- Beacon Biosignals, a leading computational neurodiagnostics and EEG analytics company, has appointed David Matthews, PhD, as Chief Business Officer to oversee commercial and strategic activities.

Key Points: 
  • Beacon Biosignals partners with top biopharma companies to better understand brain health using clinical-grade EEG and AI-powered analysis.
  • The company's Dreem 3S wearable medical device enables validated sleep endpoints at-home and unlocks a scale of brain activity data never before available.
  • Dr. Matthews will draw on his deep expertise in healthcare strategy, commercial development, and computational neuroscience to create new partnerships, expand relationships, and drive continued innovation for Beacon Biosignals through the company's next phase of growth.
  • "We are thrilled to welcome David to our leadership team," said Jacob Donoghue, MD PhD, CEO of Beacon Biosignals.

enGene Appoints Lee Giguere as Chief Legal Officer and Corporate Secretary

Retrieved on: 
Tuesday, January 30, 2024
Obsidian, Assistant, Therapy, General counsel, Corporation, Bladder cancer, Bachelor of Business Administration, Health, Business administration, Law, LEGEND, University School, BCG, Sale, Urology, NMIBC, Boston Scientific, Growth, Pharmaceutical industry

Experienced biotech executive brings public company expertise in legal, corporate governance, and compliance to support enGene during late-stage clinical development and anticipated future commercial launch of its lead program EG-70

Key Points: 
  • Experienced biotech executive brings public company expertise in legal, corporate governance, and compliance to support enGene during late-stage clinical development and anticipated future commercial launch of its lead program EG-70
    BOSTON and MONTREAL, Jan. 30, 2024 /PRNewswire/ - enGene Holdings Inc. ("enGene," (Nasdaq: ENGN), a clinical-stage genetic medicines company whose lead program is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the appointment of Lee Giguere as Chief Legal Officer and Corporate Secretary.
  • "I am delighted to welcome Lee, an experienced public biotech legal executive, to enGene as we advance the development of EG-70 in our ongoing pivotal-stage LEGEND study in BCG-unresponsive non-muscle invasive bladder cancer," said Jason D. Hanson, Chief Executive Officer of enGene.
  • Mr. Giguere previously served as Chief Legal Officer and Secretary of Obsidian Therapeutics, a clinical-stage cell and gene therapy company.
  • Mr. Giguere commented: "I am thrilled to join enGene as we work to transform the management of bladder cancer, beginning with BCG-unresponsive NMIBC.

AUA, SUO Release Amendment to Non-Muscle Invasive Bladder Cancer Guideline

Retrieved on: 
Wednesday, January 24, 2024
Death, Guideline, Woman, Patient, American Urological Association, Bladder cancer, Partnership, Society, Combination, Diagnosis, BCG, Cystoscopy, Urine, Disease, AUA, SUO, NMIBC, Dietary supplement

BALTIMORE, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Today, the American Urological Association (AUA), in partnership with the Society of Urologic Oncology (SUO), released the 2024 clinical practice guideline amendment for the diagnosis and treatment of non-muscle invasive bladder cancer.

Key Points: 
  • BALTIMORE, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Today, the American Urological Association (AUA), in partnership with the Society of Urologic Oncology (SUO), released the 2024 clinical practice guideline amendment for the diagnosis and treatment of non-muscle invasive bladder cancer.
  • Bladder cancer continues to be a significant health issue in the United States, with non-muscle invasive bladder cancer (NMIBC) accounting for approximately 75% of the estimated 82,000 new cases diagnosed in 2023.
  • “One of the fastest growing spaces in Urologic Oncology is in the treatment of non-muscle invasive bladder cancer,” said Dr. Jeffrey M. Holzbeierlein, SUO president and chair for the guideline amendment.
  • Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline: 2024 amendment.

Petroliam Nasional Berhad (PNB) Digital Transformation Strategy Analysis Report 2023: PETRONAS Ventures, Accelerators, Incubators, and Other Innovation Programs - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 24, 2024
Oil, Gas, 5G, Energy, Technology, Artificial Intelligence, Boston Consulting Group, PETRONAS, Natural gas, Microsoft, Amazon Web Services, BCG, APMS, AI, Digital, AVEVA, Investment, Acquisition, ICT, AWS, Transport, Anomaly, Marketing, Automation, Upstream, Engineering, Memorandum of understanding, Internet of things, Retail

The "Petroliam Nasional Berhad - Digital transformation strategies" company profile has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Petroliam Nasional Berhad - Digital transformation strategies" company profile has been added to ResearchAndMarkets.com's offering.
  • This report provides insight into Petronas's tech activities, including its digital transformation strategies, its innovation programs, its technology initiatives, its estimated ICT budget, and its major ICT contracts.
  • Petroliam Nasional Berhad (Petronas) is an integrated energy company engaged in exploring, developing, and producing crude oil and natural gas.
  • The company's business segments include Upstream, Downstream, Gas, Clean Energy Solutions and Project Delivery & Technology.

Believeco:Partners names Mario Simon as Chief Executive Officer

Retrieved on: 
Monday, January 29, 2024
Boston Consulting Group, Insurance, Economics, BCG, WPP, Partner, Behavioral economics, BCP, Mario, Yale University, McKinsey & Company, Health, Customer insight, Organization, Marketing, Johannes Vermeer, Management

TORONTO, Jan. 29, 2024 /PRNewswire/ - Believeco:Partners (BCP), one of North America's leading independent strategic marketing, communications and advisory firms, today announced veteran entrepreneur and global corporate strategist Mario Simon as its Chief Executive Officer.

Key Points: 
  • TORONTO, Jan. 29, 2024 /PRNewswire/ - Believeco:Partners (BCP), one of North America's leading independent strategic marketing, communications and advisory firms, today announced veteran entrepreneur and global corporate strategist Mario Simon as its Chief Executive Officer.
  • Beginning February 20, Simon will lead the agency's 300-plus team across more than 10 offices in North America.
  • For the past seven years, Mario served as Managing Director and Partner at Boston Consulting Group.
  • Prior to BCG, Mario founded, built, and led Kantar Vermeer, a marketing strategy consulting firm he created within WPP.